Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850152 | 0.80 | NPC1 (0.49) | MAPTTP53RAB9AALDH1A1HTT | |
| SCHEMBL919281 | 0.75 | HSD11B1 (0.49) | HSD11B1ALDH1A1KMT2A | |
| SCHEMBL1544452 | 0.74 | ALDH1A1 (0.43) | HSD11B1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL1544862 | 0.72 | PTGS2 (0.51) | LMNAMAPTRAB9AALDH1A1KMT2A | |
| SCHEMBL2002380 | 0.72 | DYRK1A (0.41) | HSD11B1LMNAMAPTTP53 | |
| SCHEMBL2004127 | 0.71 | DRD3 (0.32) | HSD11B1RAB9AALDH1A1HPGD | |
| SCHEMBL1999427 | 0.70 | HSD11B1 (0.35) | HSD11B1LMNAMAPTTP53RAB9A | |
| SCHEMBL9224690 | 0.70 | HSD11B1 (0.50) | HSD11B1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL9525643 | 0.70 | KDM4E (0.55) | LMNAMAPTRAB9AALDH1A1HPGD | |
| SCHEMBL12798233 | 0.70 | MAPT (0.34) | HSD11B1LMNAMAPTTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101896480-A | Tetrazole derivatives as modulators of metabotropic glutamate receptors (MGLURS) | ASTRAZENECA AB | 2010-11-24 | — | — | CN | claimed |
| EP-2231647-A1 | TETRAZOLE DERIVATES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| EP-2231647-A1 | TETRAZOLE DERIVATES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | HSD11B1 1740/4885LMNA 4242/4885MAPT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.